華仁藥業(300110.SZ):高級副總裁兼財務總監王文萍辭職
格隆匯 9 月 7日丨華仁藥業(300110.SZ)公佈,董事會於近日收到公司高級副總裁兼財務總監王文萍的書面辭職報告。王文萍因個人原因申請辭去高級副總裁兼財務總監職務,辭職後不再繼續擔任公司其他職務。
根據《公司法》、《公司章程》等相關規定,王文萍的辭職申請自送達董事會之日起生效。
王文萍原定任期自第六屆董事會第五次(臨時)會議聘任之日至第六屆董事會期限屆滿。截至本公告日,王文萍持有公司股份總數為48萬股,離職後將嚴格按照《公司法》和《深圳證券交易所上市公司股東及董事、監事、高級管理人員減持股份實施細則(2017年修訂)》相關規定,對所持股份進行管理,離職後半年內,不轉讓所持本公司股份。
公司董事會將按照相關規定儘快聘任財務總監,在聘任財務總監之前,公司董事會指定暫由董事長楊效東代為履行財務總監職責。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.